Company: NIVFW
Filing Date: 2025-05-01
Form Type: F-1/A
Source: 0001213900-25-038045
Chunk: 142

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-01
Form: F-1/A
Chunk 142
---
| ● | clients’ experience, including dedicated patient education, clinical 
 guidance and emotional support; and                                  |

| ● | access to a network of high-quality fertility specialists. |

NewGenIvf competes primarily with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf’s competitors may compete in a variety of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting brand promotions and other marketing activities. As NewGenIvf may introduce new ancillary services and other companies may introduce similar fertility services as NewGenIvf’s, NewGenIvf may become subject to additional competition. Facilities As of December 31, 2024, in addition to its clinics, NewGenIvf leased one property in Hong Kong with an aggregate square footage of approximately 8,000 for its administration support offices. NewGenIvf also operates its medical facilities as described above in “— Network of Facilities” above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs. 90 SELLING SECURITYHOLDER This prospectus relates to the possible resale from time to time by the Selling Securityholders of up to 123,275,000 Class A Ordinary Shares, which includes (i) 125,000 Class A Ordinary Shares issued to Genetics and IVF Institute pursuant to the MicroSort Purchase Agreement; (ii) 150,000 Class A Ordinary Shares issued to ASPAC pursuant to the Consulting Services Agreement; (iii) 120,000,000 Class A Ordinary Shares issuable upon the conversion of (a) the Remaining Additional Notes (as defined below), (b) the senior convertible notes exchanged on August 8, 2024 (“Exchange Notes”), (c) the exercise of Series A warrants to purchase Class A Ordinary Shares (the “Series A Warrants”), (d) the exercise of Series B warrants to purchase Class A Ordinary Shares (the “Series B Warrants”), (e) the exercise of Series C warrants to purchase Class A Ordinary Shares (the “Exchange Warrants” and together with the Series A Warrants and the Series B Warrants, the “Warrants”), and (f) the New CB Initial; and (iv) 3,000,000 Class A Ordinary Shares issuable by the Company to White Lion Capital, LLC (“White Lion”) in connection